Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene

Pediatric Nephrology

Volumn 29, Issue 1, 2014, Pages 149-153

  Román Ortiz, Elena ^a   Mendizabal Oteiza, Santiago ^a   Pinto, Sheila ^b   López Trascasa, Margarita ^c   Sánchez Corral, Pilar ^c   Rodríguez De Cordoba, Santiago ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b CSIC   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Atypical hemolytic uremic syndrome; CFH CFHR1 hybrid gene; Eculizumab; Renal transplant recipient

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANTIHYPERTENSIVE AGENT; BASILIXIMAB; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COMPLEMENT COMPONENT C4; COMPLEMENT FACTOR H; COMPLEMENT FACTOR H RELATED PROTEIN 1; COMPLEMENT FACTOR I; COTRIMOXAZOLE; CREATININE; ECULIZUMAB; MEMBRANE COFACTOR PROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEPHRITIC FACTOR; PREDNISONE; PROTEIN; TACROLIMUS; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ARTICLE; CASE REPORT; CHILD; CHILDHOOD DISEASE; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; HAPLOTYPE; HEART LEFT VENTRICLE HYPERTROPHY; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUNG EDEMA; MALE; NEPHRECTOMY; PEDIATRIC SURGERY; PRIORITY JOURNAL; SCHOOL CHILD;

ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; HEMOLYTIC-UREMIC SYNDROME; HUMANS; KIDNEY TRANSPLANTATION; MALE; MUTANT CHIMERIC PROTEINS;

EID: 84890562904     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-013-2591-8     Document Type: Article

References (13)

1. Zuber J, Le Quintrect M, Sberro-Soussan R, Loirat C, Fremeaux-Bacchi V, Legendre C (2011) New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 7:23-25
2. Zuber J, Le Quintrect M, Krid S, Bertoye C, Gueutin V, Lahoche A, Heune N, Ardissino G, Chatelet V, Noël LH, Hourmant M, Niaudet P, Fremeaux-Bacchi V, Rondeau A, Legendre C, Loirat C (2012) Eculizumab for atypical hemolytic syndrome recurrence in renal transplantation. Am J Transplant 12:3337-3354
3. Sánchez-Corral P, González-Rubio C, Rodríguez de Córdoba S, López-Trascasa M (2004) Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in Factor H. Mol Immunol 41:81-84
4. Rodríguez de Córdoba S, Tortajada A, Harris CL, Morgan P (2012) Complement dysregulation and disease: from genes and proteins to diagnostics and drugs. Immunobiology 217:1034-1046
5. Venables JP, Strain L, Routledge D, Bourn D, Powell HM, Warwicker P, Diaz-Torres ML, Sampson A, Mead P, Webb M, Pirson Y, Jackson MS, Hughes A, Wood KM, Goodship JA, Goodship TH (2006) Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 3:e431
6. Chatelet V, Fremeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B (2009) Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 9:2644-2645
7. Gruppo RA, Rother RP (2009) Eculizumab for congenital atypical hemolytic-uremic syndrome. N Eng J Med 360:544-546
8. Krid S, Roumenina LT, Beury D, Charbit M, Boyer O, Frémeaux-Bacchi V, Niaudet P (2012) Renal Transplantation Under Prophylactic Eculizumab in Atypical Hemolytic Uremic Syndrome with CFH/CFHR1 Hybrid Protein. Am J Transplant 12:1938-1944
9. Nester C, Stewart Z, Myers D (2011) Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 6:1488-1494
10. Tortajada A, Pinto S, Martínez-Ara J, López-Trascasa M, Sánchez-Corral P, Rodríguez de Córdoba S (2012) Complement factor H variants I890 and L1007 while commonly associated with atypical haemolytic uremic syndrome are polymorphisms with no functional significance. Kidney Int 81:56-63
11. Esparza-Gordillo E, Goicoechea de Jorge E, López-Trascasa M, Sánchez-Corral P, Rodríguez de Córdoba S (2005) Predisposition to atypical Hemolytic Uremic Syndrome involves the concurrence of different susceptibility alleles in the Regulators of Complement Activation gene cluster in 1q32. Hum Mol Genet 14:703-712
12. Martinez-Barricarte R, Pianetti G, Gautard R, Misselwitz J, Strain L, Fremeaux-Bacchi V, Skerka C, Zipfel P, Goodship T, Noris M, Remuzzi G, Rodríguez de Córdoba S, on behalf of the European Working Party on the Genetics of HUS (2008) The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 19:639-646
13. Zuber J, Fakouri F, Roumenia L, Loirat C, Fremeaux-Bacchi V (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8:643-657